Literature DB >> 17728712

Mechanisms of disease: angiogenesis and the management of breast cancer.

Susana Banerjee1, Mitch Dowsett, Alan Ashworth, Lesley-Ann Martin.   

Abstract

Demonstration of the clinically significant activity of bevacizumab in breast cancer has attracted a great deal of interest. Numerous other antiangiogenic treatments are in clinical development and some established therapies including tamoxifen and trastuzumab might function, in part, by suppressing angiogenesis. In this Review, we discuss the potential of various components of the angiogenic pathway as prognostic and predictive factors in breast cancer. In addition, we describe existing clinical trials of antiangiogenic agents and the challenges facing the clinical development and optimum use of these agents for the treatment of breast cancer.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17728712     DOI： 10.1038/ncponc0905

Source DB:  PubMed          Journal:  Nat Clin Pract Oncol        ISSN： 1743-4254


  47 in total

1.  Targeting Notch1 inhibits invasion and angiogenesis of human breast cancer cells via inhibition Nuclear Factor-κB signaling.

Authors:  Yuan Liu; Chuanfu Su; Yuqing Shan; Shouxiang Yang; Guifeng Ma
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 2.  Multiscale imaging and computational modeling of blood flow in the tumor vasculature.

Authors:  Eugene Kim; Spyros Stamatelos; Jana Cebulla; Zaver M Bhujwalla; Aleksander S Popel; Arvind P Pathak
Journal:  Ann Biomed Eng       Date:  2012-05-08       Impact factor: 3.934

3.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Elena V Rosca; Farhad Vesuna; Paul T Winnard; Venu Raman; Zaver M Bhujwalla; Aleksander S Popel
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

Review 4.  Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer.

Authors:  Thuy Vu; Mark X Sliwkowski; Francois X Claret
Journal:  Biochim Biophys Acta       Date:  2014-07-25

5.  Targeting the IKKβ/mTOR/VEGF signaling pathway as a potential therapeutic strategy for obesity-related breast cancer.

Authors:  Chun-Te Chen; Yi Du; Hirohito Yamaguchi; Jung-Mao Hsu; Hsu-Ping Kuo; Gabriel N Hortobagyi; Mien-Chie Hung
Journal:  Mol Cancer Ther       Date:  2012-07-23       Impact factor: 6.261

Review 6.  Angiogenesis inhibitors in the treatment of prostate cancer.

Authors:  Paul G Kluetz; William D Figg; William L Dahut
Journal:  Expert Opin Pharmacother       Date:  2010-02       Impact factor: 3.889

7.  Targeting angiogenesis in metastatic breast cancer.

Authors:  Sangeetha Reddy; Michael Raffin; Virginia Kaklamani
Journal:  Oncologist       Date:  2012-07-27

8.  Endothelial cells enhance prostate cancer metastasis via IL-6→androgen receptor→TGF-β→MMP-9 signals.

Authors:  Xiaohai Wang; Soo Ok Lee; Shujie Xia; Qi Jiang; Jie Luo; Lei Li; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Cancer Ther       Date:  2013-03-27       Impact factor: 6.261

9.  Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Authors:  Carlos H Barrios; Mei-Ching Liu; Soo Chin Lee; Laurence Vanlemmens; Jean-Marc Ferrero; Toshio Tabei; Xavier Pivot; Hiroji Iwata; Kenjiro Aogi; Roberto Lugo-Quintana; Nadia Harbeck; Marla J Brickman; Ke Zhang; Kenneth A Kern; Miguel Martin
Journal:  Breast Cancer Res Treat       Date:  2010-03-26       Impact factor: 4.872

10.  Human Sulfatase 2 inhibits in vivo tumor growth of MDA-MB-231 human breast cancer xenografts.

Authors:  Sarah M Peterson; Andrea Iskenderian; Lynette Cook; Alla Romashko; Kristen Tobin; Michael Jones; Angela Norton; Alicia Gómez-Yafal; Michael W Heartlein; Michael F Concino; Lucy Liaw; Paolo G V Martini
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.